Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, an androgen receptor blocker, significantly increased hair density, thickness, and length in monkeys when applied topically daily for several months.

Combining RU58841 and minoxidil significantly increases hair growth.

Topical eye β-blockers may cause hair loss.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

Enhancing immune response can improve cancer treatment effectiveness.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

Dutasteride effectively and safely treats male hair loss for over a year.

YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

Modern lifestyles, including poor diet, stress, and long-term use of certain medications, hinder the body's ability to heal from inflammation, leading to chronic diseases.

Most youth with gender dysphoria received hormones, had minor complications, and showed a decrease in suicide attempts after treatment.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.

More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.

The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

Some common medications can harm male fertility, but many effects can be reversed.

The document suggests a personalized treatment plan for alopecia areata based on the patient's age and hair loss severity, using a range of therapies ranked by effectiveness and safety.

The conclusion is that published guidelines are improving transgender medical care, but more research and education in transgender medicine are needed.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.

Alpha-blockers are recommended first for recent CP/CPPS, while antimicrobials are not advised for long-term cases.

New treatments for Dissecting cellulitis show promise, but more research is needed to understand the disease and establish a standard treatment plan.

Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.

Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.